Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 15 studies | 27% ± 7% | |
endothelial cell of lymphatic vessel | 12 studies | 29% ± 16% | |
CD16-positive, CD56-dim natural killer cell, human | 11 studies | 29% ± 7% | |
ciliated cell | 11 studies | 30% ± 13% | |
basal cell | 8 studies | 32% ± 13% | |
epithelial cell | 7 studies | 30% ± 13% | |
enterocyte | 7 studies | 33% ± 12% | |
endothelial cell of vascular tree | 7 studies | 22% ± 7% | |
fibroblast | 6 studies | 24% ± 10% | |
adipocyte | 6 studies | 21% ± 4% | |
transit amplifying cell | 5 studies | 21% ± 4% | |
endothelial cell | 5 studies | 20% ± 3% | |
secretory cell | 4 studies | 31% ± 9% | |
epithelial cell of proximal tubule | 4 studies | 36% ± 11% | |
club cell | 4 studies | 29% ± 12% | |
endothelial cell of artery | 4 studies | 21% ± 3% | |
vein endothelial cell | 4 studies | 30% ± 12% | |
respiratory goblet cell | 3 studies | 26% ± 15% | |
intestinal crypt stem cell | 3 studies | 28% ± 15% | |
abnormal cell | 3 studies | 43% ± 17% | |
progenitor cell | 3 studies | 38% ± 6% | |
astrocyte | 3 studies | 32% ± 10% | |
alveolar macrophage | 3 studies | 38% ± 4% | |
capillary endothelial cell | 3 studies | 25% ± 7% | |
Mueller cell | 3 studies | 37% ± 4% | |
goblet cell | 3 studies | 24% ± 4% | |
hepatocyte | 3 studies | 45% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 7783.01 | 226 / 226 | 99% | 269.99 | 403 / 406 |
kidney | 99% | 4687.78 | 88 / 89 | 88% | 103.20 | 794 / 901 |
stomach | 91% | 7562.84 | 328 / 359 | 82% | 57.43 | 234 / 286 |
lung | 98% | 2790.77 | 566 / 578 | 70% | 208.38 | 804 / 1155 |
esophagus | 88% | 1526.71 | 1274 / 1445 | 78% | 167.50 | 142 / 183 |
pancreas | 78% | 1066.37 | 255 / 328 | 87% | 64.65 | 155 / 178 |
intestine | 76% | 6475.57 | 735 / 966 | 82% | 58.26 | 431 / 527 |
bladder | 81% | 3182.33 | 17 / 21 | 74% | 125.08 | 371 / 504 |
adrenal gland | 90% | 2608.67 | 231 / 258 | 43% | 23.81 | 99 / 230 |
breast | 100% | 5999.82 | 459 / 459 | 26% | 10.50 | 287 / 1118 |
uterus | 76% | 897.22 | 129 / 170 | 46% | 65.69 | 210 / 459 |
thymus | 91% | 1532.60 | 594 / 653 | 15% | 10.21 | 88 / 605 |
brain | 52% | 552.41 | 1380 / 2642 | 50% | 19.80 | 354 / 705 |
ureter | 0% | 0 | 0 / 0 | 100% | 39.97 | 1 / 1 |
adipose | 100% | 6511.46 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 91% | 2443.40 | 1221 / 1335 | 0% | 0 | 0 / 0 |
skin | 88% | 1350.49 | 1594 / 1809 | 3% | 1.19 | 12 / 472 |
muscle | 82% | 3508.70 | 659 / 803 | 0% | 0 | 0 / 0 |
heart | 80% | 1177.71 | 693 / 861 | 0% | 0 | 0 / 0 |
ovary | 57% | 628.23 | 102 / 180 | 15% | 5.61 | 64 / 430 |
prostate | 38% | 407.00 | 94 / 245 | 5% | 2.66 | 23 / 502 |
tonsil | 0% | 0 | 0 / 0 | 27% | 29.01 | 12 / 45 |
peripheral blood | 20% | 218.73 | 189 / 929 | 0% | 0 | 0 / 0 |
spleen | 2% | 16.66 | 4 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016488 | Biological process | farnesol catabolic process |
GO_0007584 | Biological process | response to nutrient |
GO_0044597 | Biological process | daunorubicin metabolic process |
GO_0030216 | Biological process | keratinocyte differentiation |
GO_0071799 | Biological process | cellular response to prostaglandin D stimulus |
GO_1900053 | Biological process | negative regulation of retinoic acid biosynthetic process |
GO_0019371 | Biological process | cyclooxygenase pathway |
GO_0048385 | Biological process | regulation of retinoic acid receptor signaling pathway |
GO_0044598 | Biological process | doxorubicin metabolic process |
GO_0071395 | Biological process | cellular response to jasmonic acid stimulus |
GO_2000224 | Biological process | regulation of testosterone biosynthetic process |
GO_0042448 | Biological process | progesterone metabolic process |
GO_0071384 | Biological process | cellular response to corticosteroid stimulus |
GO_0061370 | Biological process | testosterone biosynthetic process |
GO_0009267 | Biological process | cellular response to starvation |
GO_0071277 | Biological process | cellular response to calcium ion |
GO_0001523 | Biological process | retinoid metabolic process |
GO_0070293 | Biological process | renal absorption |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0042574 | Biological process | retinal metabolic process |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0071379 | Biological process | cellular response to prostaglandin stimulus |
GO_0042572 | Biological process | retinol metabolic process |
GO_0006693 | Biological process | prostaglandin metabolic process |
GO_0008584 | Biological process | male gonad development |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0043170 | Biological process | macromolecule metabolic process |
GO_0008202 | Biological process | steroid metabolic process |
GO_2000353 | Biological process | positive regulation of endothelial cell apoptotic process |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0047024 | Molecular function | 5alpha-androstane-3beta,17beta-diol dehydrogenase activity |
GO_0047086 | Molecular function | ketosteroid monooxygenase activity |
GO_0018636 | Molecular function | phenanthrene 9,10-monooxygenase activity |
GO_0004032 | Molecular function | aldose reductase (NADPH) activity |
GO_0047044 | Molecular function | androstan-3-alpha,17-beta-diol dehydrogenase activity |
GO_0016655 | Molecular function | oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor |
GO_0047023 | Molecular function | androsterone dehydrogenase activity |
GO_0045703 | Molecular function | ketoreductase activity |
GO_0036131 | Molecular function | prostaglandin D2 11-ketoreductase activity |
GO_0004033 | Molecular function | aldo-keto reductase (NADPH) activity |
GO_0047035 | Molecular function | testosterone dehydrogenase (NAD+) activity |
GO_0001758 | Molecular function | retinal dehydrogenase activity |
GO_0036130 | Molecular function | prostaglandin H2 endoperoxidase reductase activity |
GO_0052650 | Molecular function | all-trans-retinol dehydrogenase (NADP+) activity |
GO_0032052 | Molecular function | bile acid binding |
GO_0047017 | Molecular function | prostaglandin F synthase activity |
GO_0047045 | Molecular function | testosterone 17-beta-dehydrogenase (NADP+) activity |
GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
GO_0047787 | Molecular function | Delta4-3-oxosteroid 5beta-reductase activity |
GO_0045550 | Molecular function | geranylgeranyl reductase activity |
GO_0004745 | Molecular function | all-trans-retinol dehydrogenase (NAD+) activity |
GO_0035410 | Molecular function | dihydrotestosterone 17-beta-dehydrogenase activity |
GO_0047020 | Molecular function | 15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity |
Gene name | AKR1C3 |
Protein name | Aldo-keto reductase family 1 member C3 (EC 1.1.1.-) (EC 1.1.1.210) (EC 1.1.1.53) (EC 1.1.1.62) (17-beta-hydroxysteroid dehydrogenase type 5) (17-beta-HSD 5) (3-alpha-HSD type II, brain) (3-alpha-hydroxysteroid dehydrogenase type 2) (3-alpha-HSD type 2) (EC 1.1.1.357) (Chlordecone reductase homolog HAKRb) (Dihydrodiol dehydrogenase 3) (DD-3) (DD3) (Dihydrodiol dehydrogenase type I) (HA1753) (Prostaglandin F synthase) (PGFS) (EC 1.1.1.188) (Testosterone 17-beta-dehydrogenase 5) (EC 1.1.1.239, EC 1.1.1.64) Aldo-keto reductase family 1 member C3 (Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II), isoform CRA_a) Aldo-keto reductase family 1 member C3 |
Synonyms | PGFS KIAA0119 DDH1 hCG_19343 HSD17B5 |
Description | FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone . Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH . Acts preferentially as a 17-ketosteroid reductase and has the highest catalytic efficiency of the AKR1C enzyme for the reduction of delta4-androstenedione to form testosterone . Reduces prostaglandin (PG) D2 to 11beta-prostaglandin F2, progesterone to 20alpha-hydroxyprogesterone and estrone to 17beta-estradiol . Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) . Also displays retinaldehyde reductase activity toward 9-cis-retinal . . |
Accessions | ENST00000439082.7 ENST00000605149.5 S4R3Z2 P42330 A0A0A0MSS8 ENST00000602997.5 ENST00000380554.5 [P42330-1] S4R3D5 |